Dr. Michael Kiebish of BPGbio shares insight into its AI-powered NAi Interrogative Biology Platform and discusses the growing importance of multiomic data
3 Apr 2025 by Charlie Carter, Life Sciences Editor
Excerpt:
“Despite the growing interest in AI and machine learning, many AI-driven therapeutic approaches have failed to meet expectations, with a high failure rate in clinical trials and regulatory approvals. BPGbio stands out as a notable exception, with several assets currently in phase 2b trials for aggressive cancers and no failed clinical trials to date. Its success can be attributed to the integration of clinically annotated data with full multiomic datasets, feeding its Bayesian/causal AI model, the NAi Interrogative Biology Platform.
This approach combines systems biology, integrative biology, and cutting-edge AI to uncover causal relationships in disease biology, which is especially critical for understanding co-morbidities and the intricate interactions between inflammation, metabolic disease, and neurological disease.”
For the full article, please visit the SelectScience website: How Multiomics and AI Advance Drug Discovery
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Contact
Media Contact:
media@bpgbio.com
